Navigation Links
PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
Date:11/6/2007

ANNAPOLIS, Md., Nov. 6 /PRNewswire-FirstCall/ -- PharmAthene (Amex: PIP), a biodefense company specializing in the development of medical countermeasures against biological and chemical threats, will webcast its third quarter 2007 financial results conference call on Tuesday, November 13, 2007 at 4:30 p.m. Eastern Time. David Wright, President and Chief Executive Officer and Christopher Camut, Vice President and Chief Financial Officer will review the Company's operations, business outlook and current financial results. A press release announcing the third quarter results will be issued at 4:00 p.m. E.T. on Tuesday, November 13, 2007, and be available on the Company's website.

Conference Call Information

To access the call, the dial-in number within the United States is 866-510-0676. The dial-in number for international callers is 617-597-5361. The participant passcode is 15368854.

Conference Call Replay

A replay of the conference call will be available for 30 days, beginning at approximately 6:30 p.m. E.T. November 13th, 2007 until approximately 11:59 p.m. E.T. on December 13, 2007. The dial-in number from within the United States is 888-286-8010. For international callers, the dial-in number is 617-801-6888. The participant passcode is 84931672.

Webcast

The conference call will be also be webcast live and is accessible from the company's website at http://www.pharmathene.com. A link to the webcast may be accessed on the home page or under the 'Investor Relations' section of the website. The replay of the call will be available via webcast for 30 days, or until December 13, 2007.

About PharmAthene, Inc.

PharmAthene is a biodefense company formed in 2001 to meet the critical needs of the United States by developing biodefense products. PharmAthene is dedicated to the rapid development of important and novel biotherapeutics to address biological pathogens and
'/>"/>

SOURCE PharmAthene
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
2. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
3. Biopure Announces 2007 Third Quarter Financial Results
4. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
5. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
6. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
7. Pharmacopeia Announces Third Quarter 2007 Financial Results
8. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
9. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
10. Spherix Reports Second Quarter Earnings
11. Tapestry Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2008)...KLIN, Mass., Nov. 26 PLC...d today that it has received full approval from th...U.S. pivotal trial to study the effectiveness of t... therapy in the prevention of Contrast-Induced Nep...LC,s request to expand their investigation from th...
(Date:11/25/2008)...re-FirstCall/ -- Poniard,Pharmaceuticals, Inc. (N...ed on,innovative oncology therapies, announced to...ves for its preclinical research programs in order...he clinical development of picoplatin,its lead p...rcialization of,picoplatin in the treatment of sm...
(Date:11/24/2008)...no,s Pizza (NYSE: DPZ ), the,recognized world l...ugh for,the kids of St. Jude Children,s Research ...g campaign. Domino,s customers will have the oppor... benefit the children of St. Jude.,Donations can ...ing online at, www.dominos.com . The campaign beg...
(Date:11/24/2008)...l/ -- Schering-Plough Corporation (NYSE: SGP ) t...ctive adenosine2a receptor antagonist, met the pri...patients suffering from moderate to severe Parkins...bnormal involuntary movements (dyskinesias). The ...s 2008 R&D Update meeting being hosted for ana...
Breaking Medicine Technology:PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4FierceBiotech Names NanoBio Corporation as One of the Fierce 15 Biotech Companies of 2008 6188 1FierceBiotech Names NanoBio Corporation as One of the Fierce 15 Biotech Companies of 2008 6188 2New cardiovascular score developed to improve heart attack and stroke detection 22648 1New cardiovascular score developed to improve heart attack and stroke detection 22648 23rd Annual Conference on Pain Jointly Sponsored By Rehabilitation Institute of Chicago and MediCom Worldwide Inc 22643 13rd Annual Conference on Pain Jointly Sponsored By Rehabilitation Institute of Chicago and MediCom Worldwide Inc 22643 2Heart Disease and Diabetes Finally Meet Their Match With Delicious New Snack Bars From WatchDog Nutrition 28TM 29 22638 1Heart Disease and Diabetes Finally Meet Their Match With Delicious New Snack Bars From WatchDog Nutrition 28TM 29 22638 2
...cified subset analyses of progression-free surviva...ate a reduction in,relative risk of disease progre...alyses included prior Taxotere use,geographies, a...une 04, 2007 /PRNewswire-FirstCall/ -- Pharmion,Co...resentation of,additional data from the double-bli...
...., June 04, 2007 /PRNewswire-FirstCall/ -- Boston,...ion of an article,in the Journal of of Cardiology ...hich evaluates the Company,s second-generation,TAX...em. The,article in the April 24 edition of JACC co...bailout rate of the TAXUS Liberte Stent,system com...
Other Medicine Technology:Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 2Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 3Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 4
(Date:12/1/2008)...wire-FirstCall/ -- The Ensign Group, Inc.,(Nasdaq... Rehabilitation Center in,Pocatello, Idaho has su... and,Medicaid Services, Special Focus program. ,...h/20071213/LATH168LOGO ) , A clinical team ...llo Care,& Rehabilitation Center, completed t...
(Date:12/1/2008)..., at Memorial Sloan-Kettering Cancer Center, New Y... expression of genes for therapeutic purposes, and... in mice. , Small, noncoding RNA molecules known... expression. In the study, the miRNA miR-181a was ...ne cells known as T cells at different stages of t...
(Date:12/1/2008)...irstCall/ -- ViroPharma Incorporated,(Nasdaq: V... supplemental,Biologics License Application (sBLA...for Cinryze(TM) C1 Inhibitor (human) as a treatmen...). , The sBLA is based on a re-analysis and...e treatment study of Cinryze and interim data from...
(Date:12/1/2008)...ty illnesses common, study shows , , MO...ders are common among young adults in the United S... , To reach this finding, U.S. researchers anal...9 to 25, who took part in the National Epidemiolog...The study found that 45.8 percent of the 2,188 col...
Breaking Medicine News(10 mins):Health News:The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program 2Health News:The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 5Health News:Few Young Adults Seek Treatment for Psych Disorders 2
...der unsanitary and freezing conditions in the coun...e and shell marine products.// The National Instit...bad conducted a study which reveals that many amon...n working in fish processing units are predominant...
...d that more devastating earthquakes are likely to ...50 years. // They will inflict far greater damage ... in Pakistan. Roger Bilham who has been working i... the past two months, said that a huge amount of e...
... Journal of Psychiatry that antidepressant drugs d...rather decrease the suicide risk. The article also...nt drugs should be closely monitored to find their... dosage can cause adverse conditions. The resea...
...nd news media to increase the awareness about chil...// to increase child survival. The Lancet reports ...achievable, Millennium Development Goal – 4 (MDG) ...en below the age of 5 and MDG-5 wants a reduction ...
Other Medicine News:Health News:Unregulated Fish Industry Harms Health Of Women 2Health News:More Severe Earthquakes May Hit Kashmir In Future 2
Clinician's Pocket Drug Reference 2005 includes key elements of commonly used medications that are essential information for both the student and practicing physician.
AHFS Patient Drug Information gives you a single source for providing important information and instructions for patients on dosing, precautions, possible side effects and interactions, and more.
Containing more than 600 full drug monographs, plus abbreviated monographs for combination drugs, orphan drugs and AIDS drugs in development, A to Z Drug Facts provides up-to-date information on more
Provides instant access to reliable information on herbs, minerals, vitamins, amino acids, probiotics, enzymes, over-the-counter hormones, and other dietary supplements commonly used by consumers.
Medicine Products: